Clinical Trial: Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07799025) titled 'Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects' on Aug. 24.

Brief Summary: This is a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of MWX203 Injection in healthy Chinese subjects.

The study comprises six dose cohorts with a planned enrollment of 54 subjects. The primary endpoint is safety, assessed by adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms. Secondary endpoints include plasma PK para...